<DOC>
	<DOCNO>NCT00003230</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I/II trial study effectiveness paclitaxel treat patient refractory recurrent acute leukemia chronic myelogenous leukemia .</brief_summary>
	<brief_title>Paclitaxel Treating Patients With Refractory Recurrent Acute Leukemia Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose paclitaxel give 96-hour infusion patient acute leukemia refractory recurrent standard chemotherapy , patient blast crisis chronic myelogenous leukemia , elderly patient ( 65-75 ) newly diagnose acute leukemia . II . Determine rate complete partial remission paclitaxel treatment patient . III . Assess toxic effect paclitaxel give 96-hour infusion patient . IV . Determine duration remission paclitaxel treatment patient population . OUTLINE : This dose escalation , multicenter study . Patients receive paclitaxel 96-hour continuous infusion . Patients may receive second course treatment 4 week absence unacceptable toxicity irrespective treatment result 1 course . Cohorts 3 patient treat escalate dos paclitaxel absence dose limit toxicity ( DLT ) . If 1 3 patient develops DLT , 3 additional patient treat dose level . If DLT occur 1 3-6 patient , dose escalation stop consider maximum tolerate dose ( MTD ) . Once MTD define , next patient enter dose level precede MTD phase II portion study . Patient follow 2 week completion study every 3-6 month thereafter . PROJECTED ACCRUAL : There total 33 patient accrue ( 22 patient first stage 11 second stage ) study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm acute myelogenous leukemia ( AML ) , acute lymphoblastic leukemia ( ALL ) Bcell Tcell type , blast crisis chronic myelogenous leukemia ( CML ) Must fulfill one follow criterion : Newly diagnose , previously untreated AML ALL elderly patient ( 65 75 ) First subsequent relapse AML ALL standard chemotherapy , autologous allogeneic bone marrow transplantation , highdose treatment peripheral blood stem cell support AML ALL refractory standard chemotherapy ( complete remission achieve 2 course conventional induction chemotherapy ) CML blast crisis subtype ( i.e. , myelogenous lymphoblastic ) without previously know chronic phase No leukemic involvement central nervous system PATIENT CHARACTERISTICS : Age : 18 75 Performance status : WHO 03 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 1.25 time upper limit normal ( ULN ) Renal : Creatinine le 1.25 time ULN Cardiovascular : No history atrial ventricular arrhythmia No history congestive heart failure , even medically control No history document myocardial infarction Neurologic : No motor sensory neuropathy grade 2 No dementia significantly alter mental status Other : HIV negative No active infection serious underlie medical condition No prior allergic reaction drug contain Cremophor EL No complete bowel obstruction Not pregnant nursing Adequate contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : No required concurrent cytoreductive treatment addition paclitaxel No concurrent growth factor cytokine No concurrent immunotherapeutic drug Chemotherapy : No prior paclitaxel relate compound malignancy leukemia No required concurrent cytoreductive treatment addition paclitaxel Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
</DOC>